In diabetic rats, oral administration of a curcumin-containing formulation was associated with fewer retinal vascular abnormalities and lower GFAP immunoreactivity, accompanied by parallel differences in inflammasome-related proteins.
Abstract
Background: Diabetic retinopathy (DR) is a leading cause of vision loss, with oxidative stress and inflammation serving as critical drivers of its onset and progression. Curcumin, a natural polyphenol, is known for its potent anti-inflammatory and antioxidant properties. Glial fibrillary acidic protein (GFAP) is commonly used as an indicator of retinal macroglial reactivity, whereas the NLRP3 inflammasome is an important mediator of inflammatory signaling in DR. We evaluated retinal vascular abnormalities and retinal GFAP immunoreactivity and examined whether these findings were accompanied by changes in retinal NLRP3 and IL-1β protein abundance and in the levels of cleaved caspase-1 and cleaved GSDMD. Methods: Diabetes was induced in 7-week-old rats via a single intraperitoneal injection of streptozotocin. Following the confirmation of hyperglycemia, curcumin was administered orally. To evaluate the effects, we performed trypsin digestion, haematoxylin and eosin (H&E) staining, fluorescein isothiocyanate (FITC)–dextran permeability assays, immunofluorescence staining, and Western blotting on the harvested retinas. Results: The DM group showed increased acellular capillary formation, vascular leakage, retinal GFAP immunoreactivity, NLRP3 and IL-1β protein abundance, and levels of cleaved caspase-1 and cleaved GSDMD. Compared with the untreated DM group, the DM + curcumin group showed lower values for all of these outcomes. Conclusions: In diabetic rats, oral administration of a curcumin-containing formulation was associated with fewer retinal vascular abnormalities and lower GFAP immunoreactivity, accompanied by parallel differences in inflammasome-related proteins. These findings support the potential of this formulation as an adjunctive therapeutic approach for early diabetic retinopathy.
Diabetic retinopathy (DR) is among the most common complications of diabetes mellitus and is characterized by microangiopathy and neurodegeneration. Microglia constitute a resident immune population in the central nervous system (CNS) and play crucial roles in regulating retinal angiogenesis under both physiological an...
Chun-Lai Fang, L. Qian, Ning Ma· Discover medicine· 0 citations
Cynarin protects against oxidative stress-induced retinal degeneration by suppressing MAPK and NF-κB inflammatory signaling, representing a promising therapeutic candidate for preventing or delaying NaIO3-induced dry AMD-like retinal injury.
Yue-Lin Fang, Y. Hsu, Chao-Hsien Sung et al.· Biomolecules· 0 citations
Purpose Annexin A1 (AnxA1) regulates inflammation and neovascularization in ocular diseases, influencing growth factor signaling and cytoskeletal dynamics. Accordingly, this study aimed to investigate the role of the AnxA1 protein in diabetic retinopathy (DR) and to understand how its absence affects inflammation and v...
Rafael Andrade da Silva, Luiz Philipe de Souza Ferreira, V. M. de Paiva Roda et al.· Investigative Ophthalmology...· 0 citations
These findings identify CANA as a promising therapeutic candidate for DR, acting through TLR4/NF-κB/NLRP3-dependent modulation of microglial activation and inhibited the TLR4/NF-κB/NLRP3 pathway.
Tai Guo, Yue Liu, Mengxiao He et al.· Current Eye Research· 0 citations
Targeting mitochondrial TSPO with PIGA-1138 attenuates key hallmarks of DR by mitigating oxidative stress, suppressing neuroinflammation, and preserving retinal structure and function.
Diabetic retinopathy (DR) is a major vision-threatening complication of diabetes mellitus, in which chronic inflammation and retinal microglial activation contribute to disease progression. Bromodomain-containing protein 4 (BRD4) is an epigenetic regulator involved in inflammatory transcription; however, the downstream...
Ran Wang, Li-Wen Wang, Xu Sun et al.· International Immunopharmaco...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.